Manos Perros, Entasis CEO

As­traZeneca's for­mer an­tibi­otics unit claims a PhI­II win in drug-re­sis­tant bac­te­ria af­fect­ing sick­ly pa­tients

The man­age­ment team at En­ta­sis, As­traZeneca’s old an­tibi­otics unit spun out six years ago, has a new dataset it’s sim­ply de­light­ed to share.

En­ta­sis re­vealed Phase III da­ta out­lin­ing how an an­tibi­ot­ic for in­fec­tions caused by Acine­to­bac­ter bau­man­nii reached its pri­ma­ry end­point of non-in­fe­ri­or­i­ty. Re­searchers com­pared the pro­gram — known as sul­bac­tam-dur­lobac­tam or SUL-DUR — to the an­tibi­ot­ic col­istin, say­ing their drug saw low­er lev­els of all-cause mor­tal­i­ty af­ter four weeks in treat­ment-re­sis­tant pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.